Impact of Metabolic Syndrome Diagnosis and Its Treatment on Survival of Colorectal Cancer Patients

Table 1

Demographic and clinicopathological characteristics of the sample N = 301.

Variable	Number	Percentage (%)
Age (y)
Mean ± SD (y)	55	±15.15
≤40	45	15
41-60	131	43.4
≥61	125	41.5
Gender
Male	175	58.1
Female	126	41.9
AJCC stage
1&2	78	25.9
3	104	34.6
4	119	35.9
Tumor differentiation
Well	36	12.0
Moderate	209	69.4
Poor	46	15.3
Cancer Treatment
Surgery only	34	11.3
Surgery +Systemic therapy	181	60.1
Systemic therapy only	69	22.9
No treatment	17	5.6
Obesity
No	207	68.8
Yes	95	31.2
Elevated glucose/DM
No	190	63.1
Yes	111	36.9
Hypertension
No	155	51.5
Yes	146	48.5
Dyslipidemia
No	224	74.4
Yes	77	25.6
MetS
No	225	74.8
Yes	76	25.2
Insulin use
No	240	79.7
Yes	61	20.3
Metformin use
No	229	76.1
Yes	72	23.9
Statin use
No	224	74.4
Yes	77	25.6
ACEI/ARB use
No	247	82.1
Yes	54	17.9
Other antiHTN
No	206	68.4
Yes	95	31.8
Aspirin Use
No	248	82.4
Yes	53	17.6
Anti-diabetic treatment
No Diabetes	190	63.1
Metformin	72	23.9
Other treatment	39	13.0
Status
Died	105	34.9
Censored	196	61.5

Note: AJCC: American Joint Committee on Cancer, ACEI: angiotensin converting enzyme inhibitors, DM: diabetes mellitus, antiHTN: antihypertensive, MetS: metabolic syndrome, SD: standard deviation, and other treatments: insulin and/or other oral hypoglycemic agents, except metformin.